Slide 1: Earnings Call - Q4 - FY22
1 | NASDAQ: SLP October 26, 2022 1 Earnings Call - Q4 - FY22
Slide 2: Safe Harbor Statement
2 | NASDAQ: SLP With the exception of historical information, the matters discussed in this presentation are forward- looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but th
Slide 3: Full Year Highlights
3 | NASDAQ: SLP Achievements • Continued scientific leadership in biosimulation market with expanding industry and regulatory partnerships • Accelerating revenue growth and improved profitability • Leveraging software portfolio to enhance growth • Rebuilt service backlog and returned to growth 28% D
Slide 4: Fourth Quarter & Full Year Software Highlights
4 | NASDAQ: SLP GastroPlus® MonolixSuite® +55% • 7 new commercial customers • Continued strong renewal/upsell pattern Fourth Quarter & Full Year Software Highlights -8% • 6 new commercial customers in Q4 • 7 upsells in Q4 • 14 peer reviewed journal articles published in Q4 ADMET Predictor® • 5 new c
Slide 5: Fourth Quarter & Full Year Services Highlights
5 | NASDAQ: SLP PBPK QSP/QST PKPD Fourth Quarter & Full Year Services Highlights +9% +48% +4%+3% +29% +84% FY Revenue Growth FY Revenue Growth FY Revenue Growth Q4 Revenue Growth Q4 Revenue Growth Q4 Revenue Growth General • 22% increase in backlog compared to prior year • Dynamic market for scienti
Slide 6: FY23 Outlook
6 | NASDAQ: SLP FY23 Outlook FY23 Guidance: 10% to 15% Total Revenue Growth $59.3M to $62.0M Total Revenue 60% to 65% Software Revenue % of Total Revenue 35% to 40% Service Revenue % of Total Revenue $0.63 to $0.67 Diluted EPS Commentary: • Software business continues to deliver with strong momentum
Slide 7: Financial Results
7 | NASDAQ: SLP Financial Results
Slide 8: Revenue - Q4
8 | NASDAQ: SLP Q4 Revenue (in millions) (in millions) Software RevenueTotal Revenue Services Revenue Revenue - Q4 +19% +10% +30% 4Q22 Mix 4Q21 Mix
Slide 9: Revenue - Fiscal Year
9 | NASDAQ: SLP Q4 Revenue (in millions) Software RevenueTotal Revenue Services Revenue +16% +18% +13% Revenue - Fiscal Year FY22 Mix FY21 Mix (in millions)
Slide 10: Gross Margin Trends - Q4
10 | NASDAQ: SLP Gross Margin Trends - Q4
Slide 11: Gross Margin Trends - Fiscal Year
11 | NASDAQ: SLP Gross Margin Trends - Fiscal Year
Slide 12: Software Revenue by Product
12 | NASDAQ: SLP Software Product as % of Software Revenue Q4 FY22 Other FY22 Other Software Revenue by Product
Slide 13: Software Performance Metrics - Q4
13 | NASDAQ: SLP Avg. Revenue per Customer (in thousands) Software Performance Metrics - Q4 Commercial Customers Renewal Rates
Slide 14: Software Performance Metrics - Fiscal Year
14 | NASDAQ: SLP Avg. Revenue per Customer (in thousands) Renewal Rates Software Performance Metrics - Fiscal Year Commercial Customers University+ Customers: 245 in 53 countries
Slide 15: Service Revenue by Type
15 | NASDAQ: SLP Services as % of Service Revenue 4Q22 FY22 Service Revenue by Type PKPD QSP/QST PBPK Other PKPD QSP/QST PBPK Other
Slide 16: Services Performance Metrics: Backlog and Total Projects
16 | NASDAQ: SLP Backlog Services Performance Metrics Total Projects
Slide 17: Income Statement Summary - Q4
17 | NASDAQ: SLP Income Statement Summary - Q4 (in millions, except Diluted EPS) 4Q22 % of Rev 4Q21 % of Rev Revenue $11.7 100% $9.8 100% Revenue growth 19% 3% Gross profit 9.1 77% 7.1 72% R&D 0.8 7% 1.3 13% SG&A 7.6 65% 5.6 57% Total operating exp 8.4 71% 6.9 70% Income from operations 0.7 6% 0.2 2
Slide 18: Income Statement Summary - Fiscal Year
18 | NASDAQ: SLP Income Statement Summary - Fiscal Year (in millions, except Diluted EPS) FY22 % of Rev FY21 % of Rev Revenue $53.9 100% $46.5 100% Revenue growth 16% 12% Gross profit 43.1 80% 35.9 77% R&D 3.2 6% 4.0 9% SG&A 25.0 46% 20.6 44% Total operating exp 28.2 52% 24.6 53% Income from operati
Slide 19: Balance Sheet Summary
19 | NASDAQ: SLP Balance Sheet Summary (in millions) August 31, 2022 August 31, 2021 Cash and short-term investments $128.2 $123.6 Total current assets 146.8 139.3 Total assets $188.4 $180.0 Current liabilities 7.7 11.6 Long-term liabilities 2.4 2.6 Total liabilities 10.1 14.2 Shareholders’ equity 1
Slide 20: Conclusion
20 | NASDAQ: SLP Conclusion • Delivering on our commitment to scientific leadership ◦ Internal R&D investment ◦ Expanding industry and regulatory partnerships • Enhancing our client facing capabilities ◦ Growth and maturity of business development team ◦ Focus on expanding our local coverage of EU m